Please check your internet connection and try again.
# Aclidinium Bromide (Walethmade)
*Note: The common trade name is Tudorza Pressair. "Walethmade" does not correspond to a recognized pharmaceutical generic name; assuming "Aclidinium bromide" based on user intent.*
## Overview
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that acts as a potent competitive antagonist at M3 muscarinic receptors in the airway smooth muscle, leading to smooth muscle relaxation and bronchodilation. It is delivered via a dry powder inhaler (DPI).
## Primary Indications
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
## Adult Dosing
400 mcg (one inhalation) twice daily.
* **Maximum Dose:** 800 mcg per 24 hours.
## Pediatric Dosing
Not indicated for pediatric use. Safety and efficacy in patients under 18 years of age have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:** No dose adjustment necessary.
* **Geriatric:** No dose adjustment necessary.
## Contraindications
* Hypersensitivity to aclidinium bromide, atropine, or any components of the inhalation powder.
* Not indicated for the relief of acute bronchospasm (rescue therapy).
## Adverse Effects
* **Common:** Headache, nasopharyngitis, cough, sinusitis.
* **Serious:** Paradoxical bronchospasm, worsening of narrow-angle glaucoma, urinary retention, or hypersensitivity reactions (anaphylaxis/angioedema).
## Key Drug Interactions
* **Anticholinergics:** Use with other anticholinergic-containing drugs may increase systemic anticholinergic adverse effects. Avoid concomitant use.
* **Cimetidine:** May increase plasma concentrations; monitor for increased anticholinergic effects.
## Monitoring
* Monitor for paradoxical bronchospasm upon administration (discontinue if occurs).
* Assess lung function (FEV1) to evaluate therapeutic response.
* Monitor for worsening of urinary retention and narrow-angle glaucoma, especially in elderly patients.
## Clinical Pearls
* **Inhalation Technique:** Breath-actuated inhaler; ensure the patient takes a deep, rapid, and full breath.
* **Indication:** Must reinforce that this is not a rescue inhaler for acute symptoms; patients must have a short-acting beta-agonist (e.g., albuterol) available for rescue.
* **Visual Indicator:** The inhaler has a dose indicator and a colored control window (green to red) to confirm the dose has been successfully inhaled.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and prescribing information (package inserts) may change. Always verify specific dosing, safety data, and contraindications via the most current institutional formulary, pharmacology databases (e.g., Lexicomp, UpToDate), or the FDA-approved product label before prescribing or administering medication.
